Table 2.
Rate of VTE recurrences and major bleeding events—stratified by duration of therapy1
| All treated patients (N = 1158) | DOT 0 to 3 months (N = 629) | DOT 3 to 6 months (N = 244) | DOT over 6 months (N = 285) | |
|---|---|---|---|---|
| Follow-up (months)2 mean ± SD [median] | 13.7 ± 7.6 [12.3] | 10.9 ± 7.1 [8.8] | 14.9 ± 6.9 [13.4] | 19.0 ± 6.0 [18.4] |
| VTE recurrence3, n (%) | 233 (20.1) | 152 (24.2) | 37 (15.2) | 44 (15.4) |
| On index AC therapy, n (%) | 134 (11.6) | 80 (12.7) | 21 (8.6) | 33 (13.5) |
| Post index AC period, n (%) | 99 (8.5) | 72 (11.4) | 16 (6.6) | 11 (3.9) |
| Rate (per 100 patient-years) | 20.3 | 31.9 | 13.5 | 11.0 |
| Bleeding events4, n (%) | 141 (12.2) | 89 (14.1) | 15 (6.1) | 37 (13.0) |
| On index AC therapy, n (%) | 81 (7.0) | 50 (7.9) | 9 (3.7) | 22 (7.7) |
| Post index AC period, n (%) | 60 (5.2) | 39 (6.2) | 6 (2.5) | 15 (5.3) |
| Rate (per 100 patient-years) | 11.5 | 17.5 | 5.1 | 8.9 |
RVTE, recurrence of VTE; LMWH, low-molecular-weight heparin
1Duration of therapy was calculated from the first anticoagulant dispensing to treatment nonpersistence (i.e., a gap of more than 60 days between the end of the days of supply of a dispensing and the next dispensing of the index therapy)
2From the index treatment initiation to the end of eligibility or end of data (June 2015)
3A VTE recurrence was identified if a patient had a primary diagnosis of VTE during a hospitalization
4Major bleeding events were identified using a validated algorithm developed by Cunningham et al.